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Abstract
Background: Severe hand, foot, and mouth disease (HFMD) is sometimes associated with serious complications
such as acute heart failure that can cause substantial child mortality. N-terminal pro-brain natriuretic peptide
(NT-proBNP) is a sensitive and specific biomarker of congestive heart failure. The aim of this study was to use
plasma NT-proBNP levels to establish the severity of childhood HFMD.
Methods: A retrospective study was performed in 128 Chinese patients with severe HFMD and 88 patients
with mild HFMD treated between January 2014 and October 2015. Univariate and multiple logistic regression
analyses were used to analyze the risk factors for severe HFMD. NT-proBNP levels were analyzed in 128 severe
HFMD patients, and the predictive value of NT-proBNP was assessed by receiver operating characteristic analyses.
Results: Multivariate analysis controlling for several potential confounders showed that enterovirus 71 infection
[odds ratio (OR) 19.944, 95 % confidence interval (CI) 6.492–61.271], peripheral WBC count (OR 3.428, 95 % CI 1.186–9.
914), fasting glucose (OR 19.428, 95 % CI 2.236–168.784), procalcitonin (OR 9.084, 95 % CI 3.462–23.837, and NT-proBNP
(>125 pg/mL) (OR 16.649, 95 % CI 4.731–58.585) were each associated with the severity of HFMD. The 45 dead severe
patients had higher pre-procedural levels of NT-proBNP than the 83 cured severe patients (12776 ± 13115 versus
1435 ± 4201 pg/mL, P < 0.001). An NT-proBNP cutoff value of 982 pg/mL predicted mortality with 87 % sensitivity
and 86 % specificity.
Conclusion: Plasma NT-pro-BNP level appears to be a useful biological marker for predicting the severity and
mortality of HFMD.
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What is Known
• Severe HFMD cases and over 90 % of fatal cases were
caused by EV71. Acute heart failure is one of the most
common causes of death in severe HFMD. N-terminal
pro-brain natriuretic peptide (NT-proBNP) are useful
biomarkers for the assessment of congestive heart failure.
What is New
• EV71 infection, fasting glucose, procalcitonin (PCT)
and NT-proBNP levels were each associated with the
severity of HFMD. Plasma NT-pro-BNP level appears to
be a useful biological marker for predicting the severity
and mortality of HFMD.
Background
Severe hand, foot and mouth disease (HFMD) associated
with enterovirus (EV) 71 in children can result in high
morbidity and mortality [1–3]. Most children with
HFMD have mild symptoms including fever and cutane-
ous lesions on their hands, feet and buttocks, along with
oral lesions [4, 5]. However, in rare cases, patients may
also develop severe and life-threatening complications
such as encephalitis, acute pulmonary edema, and car-
diopulmonary failure [2, 6]. Consequently, acute heart
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and pulmonary failure is proposed as an important
cause of rapid deterioration of HFMD, leading to mor-
tality [3, 7].
Since 2008, nationwide epidemics of EV71 have oc-
curred [8–10] in China, affecting 4.5 million children,
and >3500 have died from the disease due to neurogenic
cardiopulmonary failure and brainstem encephalitis, ac-
cording to the Chinese Center for Disease Control and
Prevention (http://www.chinacdc.cn/). These outbreaks
of HFMD and high mortality represent a significant pub-
lic health problem in China. However, there is still no
available vaccine against EV71 and other enteroviruses
that cause HFMD [11–13]. Current management in the
clinic is only to relieve symptoms. Actually, it is import-
ant and arduous to predict whether patients will develop
severe or life-threatening illness at their first clinical
visit. Severe HFMD progresses quickly and has high
mortality. Feasible prognosis prediction of severe HFMD
would aid clinical decisions and management.
The 108-amino-acid (aa) pro-hormone brain-type
natriuretic peptide (BNP) was first isolated from porcine
brains in 1988 [14, 15]. BNP is a cardiac neuro-hormone
secreted from ventricular myocytes in response to in-
creased intraventricular pressure [15–17]. Once BNP has
been segregated, it divides into a biologically active 32-
aa BNP and inactive 76-aa NT-proBNP [18, 19]. Exces-
sive volume or pressure loading of the heart can lead to
increased BNP synthesis and secretion. In clinical appli-
cations, BNP levels are related to cardiac function and
are thought to be a sensitive and specific biomarker of
congestive heart failure [16, 19, 20]. Some studies have
established that BNP is a risk marker in patients with
HIV infection [21], severe sepsis [18], acute Kawasaki
disease [22], and acute Puumala hantavirus infection
[23]. A recent HFMD investigation has demonstrated
that high levels of NT-proBNP are associated with the
complication of cardiopulmonary collapse [24].
In this study, we explored the hypothesis that higher




This study was approved by the Medical Ethics Com-
mittee of the Second Affiliated Hospital of the Medical
College of Xi’an Jiaotong University and Xi’an Children’s
Hospital, Xi’an, China. A total of 2320 HFMD patients
were collected from all cases admitted to the two hospitals
between January 2014 and October 2015. We retro-
spectively enrolled 216 patients whose clinical data
were elaborate, comprising 128 Chinese patients with
severe HFMD and 88 patients with mild HFMD in this
case–control study. Among the 128 patients with se-
vere HFMD, 45 died. Children with severe HFMD were
treated as cases, while those with mild disease served as
controls and were used as the reference group when
calculating odds ratios (ORs).
The definition of HFMD was based on the criteria in
the Hand, Foot and Mouth Disease Clinical Guide (2010
edition) [25], which contains the following criteria: (1)
symptoms and signs occur during epidemics in pre-
school children; and (2) patients show typical exanthema
on the hands, feet, mouth and/or buttocks, with or
without fever. Patients with mild HFMD had rashes on
their hands, feet, mouths, and buttocks, with or without
fever. Patients with severe disease may have one of the
followings: (1) neurological manifestations; (2) respira-
tory manifestations; and (3) circulatory manifestations.
The diagnosis of fatal HFMD was based on one of the
following criteria: (1) frequent convulsions, coma and
cerebral hernia; (2) dyspnea, cyanosis, bloody frothy
sputum, and pulmonary rales; and (3) shock and circu-
latory failure. Other concomitant viruses positive for
IgM were ruled out in this study.
Pan-enterovirus RT-PCR assay for identification of EV71
infection
EV71 infection in patients with clinically suspected
HFMD was confirmed by positive EV71 identification
using pan-enterovirus real-time RT-PCR. Viral RNA
extraction from throat swabs was performed using an
RNA extraction kit (Qiagen, Germany). Real-time RT-
PCR for enterovirus was performed with the primers
5′-TCCTCCGGCCCCTGAATG -3′ and 5′-AATTGTC
ACCATAAGCAGCCA-3′. This triplex RT-PCR reaction
was performed in a 25 μL total reaction mixture contain-
ing 17 μL buffer, 1.5 μL primer and probe mix, 1.5 μL en-
zyme mix, and 5 μL extracted RNA template. On a
CFX96 Real-Time PCR Detection System (Bio-Rad Inc.,
USA) 30 min reverse transcription at 50 °C and 10 min
denaturation at 95 °C, followed by 5 circles of pro-
amplification at 94 °C for 10 s, 50 °C for 30 s, 72 °C for
30 s, and 40 cycles at 94 °C for 10 s, and 58 °C for 30 s
were performed to collect fluorescence signal.
Plasma NT-proBNP measurement
A rapid, comer cially available NT-proBNP immunoassay
(Cobas, Germany) was used for the NT-proBNP measure-
ment. Blood samples were collected by venipuncture into
standard EDTA tubes and centrifuged within 30 min of
collection. Plasma NT-proBNP was measured using a
commercially available horse-radish peroxidase, and col-
orimetric end-point assay was carried out for the quantita-
tive determination of feline NT-proBNP.
Data collection
The authors (Deng HL and Zhang YF) used standardized
forms to extract data independently from medical
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records. Detailed demographic data including sex and
age were collected from medical records. Clinical mani-
festations including highest fever temperature, vomit-
ing, limb weakness, hypersomnia, convulsion, high
blood pressure, consciousness disorder, dysfunction of
respiratory rhythm, and circulatory disturbance were
collected and 128 severe cases were identified. The la-
boratory data collected included enterovirus infection,
white blood cell (WBC) count, fasting glucose, plasma
NT-proBNP levels, myocardial enzyme spectrum [cre-
atine kinase (CK), CK-MB, lactate dehydrogenase
(LDH)] and procalcitonin (PCT).
Statistical analysis
All statistical analyses were performed using SPSS ver-
sion 13.0 (IBM, Chicago, IL, USA). Data for continuous
variables were summarized as mean ± SD or median
(range), and inter-group differences were assessed for
significance using the Wilcoxon rank-sum test or Stu-
dent’s t test. Data for categorical variables were summa-
rized as numbers and percentages, and the χ2 test was
used to assess differences between patients with mild or
severe HFMD. Univariate and multivariate logistic re-
gression analyses were used to identify risk factors asso-
ciated with severe HFMD using ORs. All variables with
a univariate P < 0.20 along with those deemed to be clin-
ically significant were considered for inclusion in multi-
variate models. Receiver operating characteristic (ROC)
method was used to define the optimal cut-off values of
baseline NT-proBNP. The threshold of significance for
all statistical tests was defined to be P < 0.05.
Results
Patient characteristics and clinical manifestations
There were 216 patients diagnosed with HFMD includ-
ing 128 severe cases, 45 of whom died (20.8 %). Table 1
shows the clinical manifestations of the 216 children
with HFMD who were eligible for enrollment. There
were significant differences between mild and severe
cases in terms of fever, peak temperature, duration of
fever, symptoms of central nervous and cardiopulmonary
systems, WBC count (>15 × 109/L), fasting glucose
(>8.3 mmol/L), current EV71 infection, CK (>229 U/L),
CK-MB (>25 U/L) and LDH (>450 U/L), PCT
(>0.1 ng/mL) and plasma NT-proBNP (log10 pg/mL)
(2.18 ± 0.35 vs 3.07 ± 0.75, P < 0.001) levels. Pan-enterovirus
real-time RT-PCR was performed to confirm the cases
caused by EV71 infection. Additional file 1: Table S1 shows
the clinical characteristics of HFMD caused by EV71. The
proportion of severe cases among children with HFMD
caused by the EV71 infection increased significantly than
non-EV71 infection (P < 0.05). The plasma NT-proBNP
(log10 pg/mL) levels in the EV71 infection cases were
Table 1 Risk factors for severe HFMD
Relevant factors Mild group
n = 88 (%)
Severe group
n = 128 (%)
P
Gender 0.817
Male 55 (62.5) 78 (60.9)
Female 33 (37.5) 50 (39.1)
Age (years) 0.557
≤ 3 65 (73.9) 99 (77.3)
3–6 23 (26.1) 29 (22.7)
Fever 81 (92.0) 128 (100.0) 0.001**
Temperature (°C) 0.000***
37.3 to ≤38 8 (9.1) 0 (0)
38–39 38 (43.2) 21 (16.4)
39–40 42 (47.7) 107 (83.6)
Duration of fever (day)
≤ 3 65 (73.9) 39 (30.5) 0.000***
> 3 23 (26.1) 89 (69.5)
Hypersomnia 2 (2.3) 118 (92.2) 0.000***
Hyperarousal 38 (43.2) 121 (94.5) 0.000***
Limb shaking 5 (5.7) 98 (76.6) 0.000***
Convulsion 2 (2.3) 33 (25.8) 0.000***
Vomiting 16 (18.2) 87 (68.0) 0.000***
Dyspnoea 0 (0) 71 (55.5) -
Pathologic reflexes 0 (0) 128 (100.0) -
Consciousness disorder 0 (0) 75 (58.6) -
Increased blood pressure 0 (0) 65 (50.8) -
Circulatory disturbance 0 (0) 75 (58.6) -
Laboratory examination
Peripheral WBC count >
15 × 109/L
12 (13.6) 56 (43.8) 0.000***
Fasting blood glucose
level > 8.3 mmol/L
1 (1.1) 62 (48.4) 0.000***
EV71-positivity 11 (12.5) 75 (58.6) 0.000***
NT-proBNP (log10 pg/mL) 2.18 ± 0.35 3.07 ± 0.75 0.000***
NT-proBNP >125 pg/mL 49 (55.7) 120 (93.8) 0.000***
Increased CK 3 (3.4) 31 (24.2) 0.000***
Increased CK-MB 36 (40.9) 58 (45.3) 0.521
Increased LDH 2 (2.3) 18 (14.1 %) 0.001**
Increased PCT 22 (25.0) 71 (55.5 %) 0.000***







HFMD hand, foot, and mouth disease, EV71 enterovirus 71, WBC White blood
cell, NT-proBNP N-terminal of the prohormone brain natriuretic peptide, CK
Creatine kinase isoenzyme, CK-MB Creatine kinase isoenzymeMB, LDH Lactate
dehydrogenase, PCT procalcitonin, IVIG Intravenous immunoglobulins
aCauses of death were acute pulmonary edema, brainstem encephalitis and
circulatory failure
*P <0.05, **P <0.01,***P <0.001
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significantly higher than non-EV71 infection (3.04 ± 0.88 vs
2.49 ± 0.58, P < 0.001).
Risk factors for severe disease
Risk factors for severe HFMD are summarized in
Table 2. In the univariate analysis, current EV71 infection
[(OR 9.906, 95 % confidence interval (CI) 4.807–20.413],
WBC count (OR 4.926, 95 % CI 2.442–9.938), fasting glu-
cose (OR 81.727, 95 % CI 11.045–604.760), PCT (OR
3.737, 95 % CI 2.061–6.777) and NT-proBNP levels
(>125 pg/mL) (OR 11.939, 95 % CI 5.205–27.383) were
risk factors for severe HFMD. In the multivariate model,
EV71 infection (OR 19.944, 95 % CI 6.492–61.271), WBC
count (OR 3.428, 95 % CI 1.186–9.914), fasting glucose
(OR 19.428, 95 % CI 2.236–168.784), PCT (OR 9.084,
95 % CI 3.462–23.837) and NT-proBNP (>125 pg/mL)
(OR 16.649, 95 % CI 4.731–58.585) were each associated
with the severity of HFMD.
NT-proBNP levels in severe HFMD
Children with severe HFMD were divided into two
groups based on cure or death. Table 3 shows that
hypersomnia, convulsion, peripheral WBC count, fasting
blood glucose level, NT-proBNP levels, CK and LDH
were associated with mortality in children with severe
HFMD (P < 0.05). The ROC curve and interactive dot
diagram for calculating the optimal cut-off value of NT-
proBNP in predicting mortality is shown in Fig. 1. At an
NT-proBNP cut-off value of >982.45 pg/mL, the sensi-
tivity and specificity were 86.7 and 85.5 %, respectively.
Discussion
We found that current EV71 infection, peripheral WBC
count, fasting glucose, PCT and NT-proBNP levels
(>125 pg/mL) were each associated with severity of
HFMD. Consequently, ROC curve analysis revealed
that an NT-proBNP value of ≥982.45 pg/mL had a
sensitivity of 86.7 % and specificity of 85.5 % in pre-
dicting death in patients with severe HFMD. There-
fore, early identification of these risk factors and
timely and effective intervention are important in
controlling mortality of severe HFMD.
Serum BNP is mainly synthesized and secreted by ven-
tricular myocytes, and increased intraventricular pres-
sure stress could modulate synthesis of BNP [15–17]. In
addition to hemodynamic stress, inflammation of the
myocardial tissue may also induce the production of
BNP [22, 26]. As a clinically valuable biomarker, NT-
proBNP can fulfill most of these criteria in patients with
heart failure and ventricular overload [27]. In the cardi-
ology literature, NT-proBNP had emerged as an inde-
pendent and crucial warning factor of clinical outcome
in patients with heart failure [19, 20]. We speculated
that fatal HFMD involves brainstem and autonomic
nerve dysfunction, leading to a “sympathetic storm” and
significantly increased catecholamine concentration in
the blood [28]. This may lead to increased blood flow to
the heart and ventricular preload, resulting in increased
NT-proBNP secretion and release. Previous studies have
reported that NT-proBNP levels are significantly in-
creased in severe HFMD, with cardiopulmonary collapse
[24] or EV71 infection [16], which is consistent with our
findings that children with severe HFMD, and those who
have died, had an increase in the levels of NT-proBNP.
EV71 is a neurotropic virus that can cause severe com-
plications involving the central neurogenic pulmonary
edema, aseptic meningitis, brainstem encephalitis, and
cardiopulmonary failure [6]. Many clinical studies have
shown that the symptoms of HFMD caused by EV71 are
more severe than those caused by other enteroviruses
[29, 30]. In this study, we found that EV71 infection was
associated with severe HFMD, which is consistent with
Table 2 ORs for severe HFMD




Gender 0.936 (0.535-1.637) 1.105 (0.442–2.759)
Age 0.828 (0.441–1.555) 2.070 (0.692–6.815)
EV71-positivity 9.906 (4.807–20.413)*** 19.944 (6.492–61.271)***
Peripheral WBC count
>15 × 109/L
4.926 (2.442–9.938)*** 3.428 (1.186–9.914)*
Fasting glucose
>8.3 mmol/L
81.727 (11.045–604.760)*** 19.428 (2.236–168.784)**
PCT >0.1 ng/mL 3.737 (2.061–6.777)*** 9.084 (3.462–23.837)***
NT-proBNP > 125 pg/mL 11.939 (5.205–27.383)*** 16.649 (4.731–58.585)***
HFMD hand, foot, and mouth disease, EV71 enterovirus 71, PCT procalcitonin, NT-proBNP N-terminal of the prohormone brain natriuretic peptide
CI Confidence interval, OR odds ratio. OR was calculated using the mild children as a reference group
aIn multivariate logistic regression model (n = 216), we controlled for age, gender, EV71-seropositivity, WBC, fasting glucose, CK, LDH, PCT and NT-proBNP. After
adjusting for potential confounding factors, there was significant difference in EV71 infection, peripheral WBC count, fasting blood glucose, PCT and plasma
NT-proBNP levels
*P <0.05, **P <0.01, ***P <0.001
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previous studies. Peripheral WBC count, increased fast-
ing glucose and PCT levels were other risk factors iden-
tified in our study, which is also consistent with other
studies. PCT is a helpful biomarker for early diagnosis of
inflammatory reactions, and high plasma PCT concen-
trations were associated with severe fatal HFMD. In-
creased fasting glucose was a significant risk factor in
fatal cases, which is consistent with previous studies.
The specific mechanism of increased fasting glucose is
still unclear.
This study had some limitations. The first was that the
cases of HFMD in this study were inpatients. We ex-
cluded outpatients because of incomplete medical re-
cords, and this may have introduced selection bias. The
second was the small sample size in our study, and this
may have led to negative results for some analyzed
factors. Further studies with larger numbers of cases are
required to confirm these results.
Conclusions
EV71 infection, peripheral WBC count, fasting glucose,
PCT and NT-proBNP levels (>125 pg/mL) were each as-
sociated with the severity of HFMD. Plasma NT-pro-
BNP level appears to be a useful biological marker for
predicting the severity and mortality of HFMD. Further
studies are needed to confirm our findings.
Additional file
Additional file 1: Table S1. The characteristics of HFMD causing by
EV71. (DOC 57 kb)
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Table 3 Risk factors associated with death of children with
severe HFMD
Relevant factors Cure group
n = 83 (%)
Death group
n = 45 (%)
P
Gender (male/female) 51/32 27/18 0.873
Age (≤3 years) 60 (72.3) 39 (86.7) 0.064
Fever 83 (100.0) 45 (100.0) -
Peak temperature (>39 °C) 69 (83.1) 38 (84.4) 0.848
Hypersomnia 73 (88.0) 45 (100.0) 0.015*
Hyperarousal 79 (95.2) 42 (93.3) 0.661
Limb shaking 60 (72.3) 38 (84.4) 0.121
Convulsion 27 (32.5) 6 (13.3) 0.018
Vomiting 56 (67.5) 31 (68.9) 0.870
Dyspnoea 30 (36.1) 45 (100.0) -
Pathologic reflexes 83 (100.0) 45 (100.0) -
Consciousness disorder 30 (36.1) 45 (100.0) -
Increased blood pressure 20 (24.1) 45 (100.0) -
Circulatory disturbance 30 (36.1) 45 (100.0) -
Laboratory examination
Peripheral WBC count >
15 × 109/L
27 (32.5) 29 (64.4) 0.001**
Fasting blood glucose
level > 8.3 mmol/L
25 (30.1) 37 (21.8) 0.000***
EV71-positivity 43 (51.8) 32 (71.1) 0.000***
NT-proBNP (pg/mL) 1435 ± 4201 12776 ± 13115 0.000***
NT-proBNP (log10 pg/mL) 2.68 ± 0.49 3.79 ± 0.61 0.000***
Increased CK 13 (15.7) 18 (40.0) 0.002**
Increased CK-MB 33 (39.8) 25 (55.6) 0.087
Increased LDH 4 (4.8) 14 (31.1) 0.000***
Increased PCT 48 (57.8) 23 (51.1) 0.465
HFMD hand, foot, and mouth disease, EV71 enterovirus 71, WBC White blood
cell, NT-proBNP N-terminal of the prohormone brain natriuretic peptide, CK
Creatine kinase isoenzyme, CK-MB Creatine kinase isoenzyme-MB, LDH Lactate
dehydrogenase, PCT procalcitonin, IVIG Intravenous immunoglobulins
*P <0.05, **P <0.01,***P <0.001
Fig. 1 ROC curve and interactive dot diagram for calculating
optimal cut-off value of NT-proBNP in predicting mortality
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